Clinical Trial Search

Primary: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug — 1; 1 Participants

Primary: Hyponatremia — 7; 10 participants

Primary: Participants With Adverse Events — 2; 0; 0; 0 Participants

Primary: Average Numeric Pain Score — 5.2; 5.8 score on a scale — p=0.7

Primary: Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk — .34; .30 mL/100 g/min

Primary: Change in Oxygen Delivery in Vulnerable Brain Regions — 3.7; 4.3 ml/100g/min — p=0.001

Primary: Mean Change in Cisternal Blood From Enrollment to Catheter Removal — -64.7 percent change

Primary: Depression — 12.33; 6 units on a scale

Primary: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) — 2; 1 Participants

Primary: Cerebral Artery Vasospasm — 16; 7 Participants

Primary: Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion) — -8; -3.4 mmHg

Primary: Number of Patients With Deep Vein Thrombosis for Safety Assessment. — 0; 3; 0; 0 participants

Primary: In-hospital Seizures — 3; 1 Participants

Primary: The Difference Between the Active and Sham Treatment Groups in Morphine Equivalence Dosage PER DAY — 0.058; 0.24 mg

Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01

Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00

Primary: Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) Levels — 11.1; 12.9 nmol/mL

Primary: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) — 719; 785 participants

Primary: mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any…

Primary: Mean Plasma Nitrite Concentration (Micromol/L) — 4.2; 4.3; 2.6 micromol/L

Primary: Infrascanner 2500™ Diagnostic Performance — 79; 65; 27; 9 Participants

Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445

Primary: Number of Participants With Detection of Hematoma Stratified by CT Positive and CT Negative Status — 158; 22; 126; 81 Participants

Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…

Primary: Procedural Success — 64 Vessels Treated

Primary: Number of Patients With Serious Device-related Adverse Events — 0 Participants

Primary: Sensitivity of InfraScanner 2000 TM to Detect Any Size Hematoma at the Patient Level — 85.6 percentage

Primary: Global Disability (Functional Outcome) Assessed Via the Ordinal Modified Rankin Score (mRS) — 32; 20; 4; 2 Participants

Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants

Primary: Rate of Recurrent Symptomatic Hemorrhage During the Two Year Follow-up Period in Patients With CASH. — 10; 11 Number of new bleeds